Stockholder Overview

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. ... 
More
 


NASDAQ CRVS (Common Stock)
$11.300.00 (0.00%)
06/23/174:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart

Stock chart for: CRVS.O.  Currently trading at $11.30 with a 52 week high of $22.14 and a 52 week low of $8.27.